ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

BCAX vs OLMA // ALTMAN Z-SCORE & DEBT/EQUITY

Bicara Therapeutics Inc. (NASDAQ) VS. Olema Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: BCAX 2 — OLMA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BCAX VS. OLMA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC BCAX OLMA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -32.80% -2.20 OLMA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -16.64% -22.88% +6.24 BCAX /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity ACTIVE — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 17.5 39.9 -22.42 OLMA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $643.9M $641.4M $2.5M BCAX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR BCAX REV OLMA REV BCAX GROSS % OLMA GROSS % BCAX FCF OLMA FCF
FY 2025 $0 $0 — — -$107.1M -$146.7M
FY 2024 $0 $0 — — -$74.8M -$104.5M
FY 2023 $0 $0 — — -$45.6M -$83.7M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BCAX // BETA —
OLMA // BETA —